Dobberpuhl Mitchell R, Maxwell Stevie, Feddock Jonathan, St Clair William, Bush Matthew L
*Department of Otolaryngology-Head and Neck Surgery, University of Kentucky Medical Center †University of Kentucky College of Medicine ‡Department of Radiation Medicine, University of Kentucky Medical Center, Lexington, Kentucky.
Otol Neurotol. 2016 Oct;37(9):1406-10. doi: 10.1097/MAO.0000000000001160.
The objectives were to evaluate the audiological outcomes, response of symptoms, and response of tumor volume in patients with glomus jugulare tumors treated solely with single fraction gamma knife radiosurgery.
Single institution retrospective review.
Academic, tertiary referral center.
The diagnosis code for glomus jugulare was used to identify patients. Only those who underwent gamma knife radiosurgery were included. Those previously treated with any modality were excluded. A total of 12 patients were included for the tumor response and symptom response data and 7 of those were included in the audiometric analysis.
Audiometric data at most recent follow-up compared with presentation, subjective improvement in pulsatile tinnitus, and change in tumor volume at most recent follow-up compared with pretreatment.
The average time to most recent follow-up was 27.6 months. There was no significant change in pure-tone average or word recognition. Pulsatile tinnitus completely resolved or improved in 80% of patients. Cranial neuropathies were stable or improved. A single patient experienced facial nerve paresis 2 years after treatment, which resolved with steroid treatment. Tumor control was 100% and the average change in tumor volume was a decrease of 37%.
Single modality gamma knife radiosurgery treatment of glomus jugulare tumors seems to be safe. Treatment results in decreased tumor volume and improved pulsatile tinnitus in most patients. There was no significant progression of hearing loss after treatment. Lower cranial nerve function remains stable in all patients.
评估仅接受单次伽玛刀放射外科治疗的颈静脉球瘤患者的听力学结果、症状反应和肿瘤体积变化。
单机构回顾性研究。
学术性三级转诊中心。
使用颈静脉球瘤的诊断编码来识别患者。仅纳入接受伽玛刀放射外科治疗的患者。排除既往接受过任何治疗方式的患者。共纳入12例患者进行肿瘤反应和症状反应数据统计,其中7例纳入听力测定分析。
将最近一次随访时的听力测定数据与初诊时进行比较,评估搏动性耳鸣的主观改善情况,以及将最近一次随访时的肿瘤体积与治疗前进行比较。
至最近一次随访的平均时间为27.6个月。纯音平均听阈或言语识别率无显著变化。80%的患者搏动性耳鸣完全缓解或改善。颅神经病变稳定或改善。1例患者在治疗后2年出现面神经麻痹,经类固醇治疗后缓解。肿瘤控制率为100%,肿瘤体积平均减小37%。
单次伽玛刀放射外科治疗颈静脉球瘤似乎是安全的。治疗可使大多数患者肿瘤体积减小,搏动性耳鸣改善。治疗后听力损失无显著进展。所有患者的低位颅神经功能保持稳定。